Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.59 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2677880 | 1.00 | EPHX2 (0.59) | EPHX2P2RX7CA12CA1CA2 | |
| SCHEMBL13882047 | 0.86 | P2RX7 (0.61) | EPHX2P2RX7GAAHTT | |
| SCHEMBL2260332 | 0.85 | CHRM1 (0.61) | EPHX2P2RX7CA12CA1CA2 | |
| SCHEMBL2678364 | 0.85 | P2RX7 (0.55) | EPHX2P2RX7CA12CA1CA2 | |
| SCHEMBL5040250 | 0.85 | P2RX7 (0.56) | EPHX2P2RX7CA12CA1CA2 | |
| Bromide SCHEMBL11408063 | 0.84 | CHRM1 (0.60) | EPHX2P2RX7CA12CA1CA2 | |
| SCHEMBL5019883 | 0.84 | CYP2D6 (0.45) | EPHX2P2RX7CA12CA1CA2 | |
| SCHEMBL1859048 | 0.82 | CYP2D6 (0.52) | EPHX2P2RX7CA12CA1CA2 | |
| SCHEMBL2679250 | 0.81 | EPHX2 (0.54) | EPHX2 | |
| SCHEMBL2679252 | 0.81 | EPHX2 (0.54) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2214487-B1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8212032-B2 | sEH inhibitors and their use | GLAXOSMITHKLINE LLC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8173805-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100249137-A1 | Novel sEH Inhibitors and Their Use | GlaxoSmithKline, LLC | 2010-09-30 | — | — | US | disclosed |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249137-A1 | Novel sEH Inhibitors and Their Use | NCEH1, CTH, EPHX1 | EPHX2 8/4885P2RX7 3827/4885CA12 1754/4885 |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | NCEH1, EPHX1, FAH | EPHX2 4/4885P2RX7 3031/4885CA12 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.